In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.
Bibliographical noteFunding Information:
Research leading to these results received funding from the European Research Council Grant Agreements 281738 to E.P. and 294390 to Y.B-N.; the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); the DKFZ-MOST cooperation; and the Israel Science Foundation (ISF) Centers of Excellence (1779/11).
© 2015, Published with license by Taylor & Francis Group, LLC.
- copy number variation
- genomic amplification
- mouse model